As a biotechnology company, they have one product candidate that is currently being studied to cure prostate cancer. This product is known as Provenge, which is also generically known as sipuleucel-T. The treatment is said to be a combination of the patient’s own blood cells with dendritic cells that are then incubated with Dendreon fusion protein (PAP-GM-CSF). This product was given the full approval of the FDA in 2010 after it passed its third phase of clinical trial. The results of the undertaking were presented during the AUA meeting in 2009. It was announced that those who were given treatment showed to have lived longer in an average of 4.1 months, than those were given placebo.
Although the drug has been given the go signal by the FDA, there was a delay in marketing the product which sparked some issues with the safety of the medication. This, however, led some people to question that the delay is mainly caused by some conflicts of interest between Dendreon and the FDA which resulted to some lawsuit and protests.
As of, Dendreon currently holds 5 US patents in the production of some possible anti-cancer agents and medications. They also have a hold over their Dendreon Cassette Technology on the application of their candidate medicine. They continue to expand their studies on Provenge with high hopes that it would yield therapeutics that would target other diseased cells.
Based in Seattle, Washington, the company has over 1490 associates employed, who have dedicated their studies to the creation of novel therapeutics that would bring hope to those afflicted with cancer.